Patents by Inventor Chi Hoon Park

Chi Hoon Park has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240090328
    Abstract: The present invention relates to a multi-component host material and an organic electroluminescent device comprising the same. By comprising a specific combination of the multi-component host compounds, the organic electroluminescent device according to the present invention can provide high luminous efficiency and excellent lifespan characteristics.
    Type: Application
    Filed: October 26, 2023
    Publication date: March 14, 2024
    Inventors: Hee-Choon AHN, Young-Kwang KIM, Su-Hyun LEE, Ji-Song JUN, Seon-Woo LEE, Chi-Sik KIM, Kyoung-Jin PARK, Nam-Kyun KIM, Kyung-Hoon CHOI, Jae-Hoon SHIM, Young-Jun CHO, Kyung-Joo LEE
  • Patent number: 11917907
    Abstract: The present disclosure relates to an organic electroluminescent device. The organic electroluminescent device of the present disclosure shows high luminous efficiency and good lifespan by comprising a specific combination of the plural kinds of host compounds and a specific hole transport compound.
    Type: Grant
    Filed: November 22, 2021
    Date of Patent: February 27, 2024
    Assignee: Rohm and Haas Electronic Materials Korea Ltd.
    Inventors: Kyoung-Jin Park, Tae-Jin Lee, Jae-Hoon Shim, Yoo Jin Doh, Hee-Choon Ahn, Young-Kwang Kim, Doo-Hyeon Moon, Jeong-Eun Yang, Su-Hyun Lee, Chi-Sik Kim, Ji-Song Jun
  • Patent number: 11192878
    Abstract: The present disclosure relates to a novel piperidine-2,6-dione derivative and a use thereof and, more specifically, to a piperidine-2,6-dione derivative compound having a structure of a thalidomide analog. A compound of chemical formula 1 according to the present disclosure specifically binds with CRBN protein, and is involved in functions thereof. Therefore, the compound of the present disclosure can be favorably used in the prevention or treatment of leprosy, chronic graft versus host disease, an inflammatory disease, or cancer, which are caused by actions of CRBN protein.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: December 7, 2021
    Assignee: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Jong Yeon Hwang, Jae Du Ha, Sung Yun Cho, Pil Ho Kim, Chang Soo Yun, Chi Hoon Park, Chong Ock Lee, Sang Un Choi, Joo Youn Lee, Sunjoo Ahn
  • Patent number: 11084824
    Abstract: The present invention relates to a pyrazolopyrimidine derivative, a preparation method thereof and a pharmaceutical composition comprising the same as an active ingredient for the prevention or treatment of cancer, autoimmune disease and brain disease. The pyrazolopyrimidine derivative of the present invention exhibits excellent Bruton's tyrosine kinase inhibition activity, so that it can be effectively used as a pharmaceutical composition for the prevention or treatment of cancer, autoimmune disease and Parkinson's disease.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: August 10, 2021
    Assignee: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Pilho Kim, Sung Yun Cho, Jae Du Ha, Hyoung Rae Kim, Jong Yeon Hwang, Chang Soo Yun, Hee Jung Jung, Chi Hoon Park, Chong Ock Lee, Chang Hoon Lee, Sunjoo Ahn
  • Patent number: 10882010
    Abstract: The present disclosure relates to a technique for manufacturing a humidifying membrane including a hydrophobic thin film-coating layer having a nano-sized crack morphology pattern on the surface of an aromatic hydrocarbon-based polymer ion exchange membrane and applying the membrane to a reverse electrodialysis process. The humidifying membrane including a hydrophobic thin film-coating layer having a nano-sized crack morphology pattern on the surface of an aromatic hydrocarbon-based polymer ion exchange membrane, manufactured according to the present disclosure, embodies a low bulk resistance of the ion exchange membrane and significantly improves ion selectivity, thereby overcoming the trade-off relationship between membrane resistance and ion selectivity, and thus may be commercially available as an anion and cation exchange membrane of a reverse electrodialysis device.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: January 5, 2021
    Assignee: Industry-University Cooperation Foundation Hanyang University
    Inventors: Young Moo Lee, Chi Hoon Park, So Young Lee, Doo Sung Hwang, Dongwon Shin, Doo Hee Cho, Kang Hyuck Lee
  • Publication number: 20200199129
    Abstract: The present invention relates to a pyrazolopyrimidine derivative, a preparation method thereof and a pharmaceutical composition comprising the same as an active ingredient for the prevention or treatment of cancer, autoimmune disease and brain disease. The pyrazolopyrimidine derivative of the present invention exhibits excellent Bruton's tyrosine kinase inhibition activity, so that it can be effectively used as a pharmaceutical composition for the prevention or treatment of cancer, autoimmune disease and Parkinson's disease.
    Type: Application
    Filed: May 14, 2018
    Publication date: June 25, 2020
    Inventors: Pilho Kim, Sung Yun Cho, Jae Du Ha, Hyoung Rae Kim, Jong Yeon Hwang, Chang Soo Yun, Hee Jung Jung, Chi Hoon Park, Chong Ock Lee, Chang Hoon Lee, Sunjoo Ahn
  • Publication number: 20200062730
    Abstract: The present disclosure relates to a novel piperidine-2,6-dione derivative and a use thereof and, more specifically, to a piperidine-2,6-dione derivative compound having a structure of a thalidomide analog. A compound of chemical formula 1 according to the present disclosure specifically binds with CRBN protein, and is involved in functions thereof. Therefore, the compound of the present disclosure can be favorably used in the prevention or treatment of leprosy, chronic graft versus host disease, an inflammatory disease, or cancer, which are caused by actions of CRBN protein.
    Type: Application
    Filed: May 11, 2018
    Publication date: February 27, 2020
    Inventors: Jong Yeon HWANG, Jae Du HA, Sung Yun CHO, Pil Ho KIM, Chang Soo YUN, Chi Hoon PARK, Chong Ock LEE, Sang Un CHOI, Joo Youn LEE, Sunjoo AHN
  • Patent number: 10516182
    Abstract: Disclosed are a polymer ion exchange membrane having a self-hydration capability at a high temperature under low humidity, a method of preparing the polymer ion exchange membrane, and a polymer electrolyte fuel cell system including the polymer ion exchange membrane. The polymer electrolyte membrane includes a hydrocarbon-based proton conductive polymercoating layer, and has a nano-crack on the hydrophobic surface and thus may secure ion conductivity and self-hydration capability under low humidity and remarkably improve electrochemical performance of an electrolyte.
    Type: Grant
    Filed: July 23, 2014
    Date of Patent: December 24, 2019
    Assignee: IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY)
    Inventors: Young Moo Lee, Chi Hoon Park, Doo Sung Hwang, So Young Lee, Dong Won Shin
  • Patent number: 10369149
    Abstract: The present invention relates to a 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: August 6, 2019
    Assignee: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Jong Yeon Hwang, Hyoung Rae Kim, Jae Du Ha, Sung Yun Cho, Hee Jung Jung, Pilho Kim, Chang Soo Yun, Chong Ock Lee, Chi Hoon Park, Chong Hak Chae, Sunjoo Ahn
  • Publication number: 20190126212
    Abstract: The present disclosure relates to a technique for manufacturing a self-humidifying membrane including a hydrophobic thin film-coating layer having a nano-sized crack morphology pattern on the surface of an aromatic hydrocarbon-based polymer ion exchange membrane and applying the membrane to a reverse electrodialysis process. The self-humidifying membrane including a hydrophobic thin film-coating layer having a nano-sized crack morphology pattern on the surface of an aromatic hydrocarbon-based polymer ion exchange membrane, manufactured according to the present disclosure, embodies a low bulk resistance of the ion exchange membrane and significantly improves ion selectivity, thereby overcoming the trade-off relationship between membrane resistance and ion selectivity, and thus may be commercially available as an anion and cation exchange membrane of a reverse electrodialysis device.
    Type: Application
    Filed: April 18, 2017
    Publication date: May 2, 2019
    Applicant: Industry-University Cooperation Foundation Hanyang University
    Inventors: Young Moo LEE, Chi Hoon PARK, So Young LEE, Doo Sung HWANG, Dongwon SHIN, Doo Hee CHO, Kang Hyuck LEE
  • Patent number: 10100019
    Abstract: The present invention relates to a N2-(2-methoxyphenyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The N2-(2-methoxyphenyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: October 16, 2018
    Assignee: Korea Research Institute of Chemical Technology
    Inventors: Pilho Kim, Hyoung Rae Kim, Sung Yun Cho, Jae Du Ha, Hee Jung Jung, Chang Soo Yun, Jong Yeon Hwang, Chi Hoon Park, Chong Ock Lee, Sunjoo Ahn, Chong Hak Chae
  • Patent number: 10053458
    Abstract: The present invention relates to a pyrimidine-2,4-diamine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for prevention or treatment of cancer comprising the same as an effective ingredient. A compound according to the present invention has the good effect of inhibiting anaplastic lymphoma kinase (ALK) activity, whereby a therapeutic effect on cancer cells having an anaplastic lymphoma kinase (ALK) fusion protein such as EML4-ALK, NPM-ALK, etc. can be enhanced and it is expected that a recurrence of cancer will be effectively inhibited. As such, the compound can be effectively used in a pharmaceutical composition for prevention or treatment of cancer.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: August 21, 2018
    Assignee: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Chang Soo Yun, Hyoung Rae Kim, Sung Yun Cho, Hee Jung Jung, Kwangho Lee, Chong Hak Chae, Chong Ock Lee, Chi Hoon Park, Pilho Kim, Jong Yeon Hwang, Jae Du Ha, Sun Joo Ahn
  • Publication number: 20180111905
    Abstract: The present invention relates to a N2-(2-methoxyphenyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The N2-(2-methoxyphenyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.
    Type: Application
    Filed: April 6, 2016
    Publication date: April 26, 2018
    Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Pilho Kim, Hyoung Rae Kim, Sung Yun Cho, Jae Du Ha, Hee Jung Jung, Chang Soo Yun, Jong Yeon Hwang, Chi Hoon Park, Chong Ock Lee, Sunjoo Ahn, Chong Hak Chae
  • Publication number: 20180104242
    Abstract: The present invention relates to a 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.
    Type: Application
    Filed: December 30, 2015
    Publication date: April 19, 2018
    Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Jong Yeon HWANG, Hyoung Rae KIM, Jae Du HA, Sung Yun CHO, Hee Jung JUNG, Pilho KIM, Chang Soo YUN, Chong Ock LEE, Chi Hoon PARK, Chong Hak CHAE, Sunjoo AHN
  • Publication number: 20170145007
    Abstract: The present invention relates to a pyrimidine-2,4-diamine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for prevention or treatment of cancer comprising the same as an effective ingredient. A compound according to the present invention has the good effect of inhibiting anaplastic lymphoma kinase (ALK) activity, whereby a therapeutic effect on cancer cells having an anaplastic lymphoma kinase (ALK) fusion protein such as EML4-ALK, NPM-ALK, etc. can be enhanced and it is expected that a recurrence of cancer will be effectively inhibited. As such, the compound can be effectively used in a pharmaceutical composition for prevention or treatment of cancer.
    Type: Application
    Filed: May 21, 2015
    Publication date: May 25, 2017
    Inventors: Chang Soo YUN, Hyoung Rae KIM, Sung Yun CHO, Hee Jung JUNG, Kwangho LEE, Chong Hak CHAE, Chong Ock LEE, Chi Hoon PARK, Pilho KIM, Jong Yeon HWANG, Jae DU HA, Sun Joo AHN
  • Patent number: 9403831
    Abstract: The present invention relates to a novel triazolopyrazine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating hyper proliferative disorder. The present invention can be useful as a therapeutic agent for various hyper proliferative disorders associated with excessive cell proliferation and growth caused by abnormal kinase activity, such as cancer, psoriasis, rheumatoid arthritis, and diabetic retinopathy, by efficiently inhibiting c-Met tyrosine kinase activity.
    Type: Grant
    Filed: September 30, 2013
    Date of Patent: August 2, 2016
    Assignees: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, HANDOK INC.
    Inventors: Hee Jung Jung, Jae Du Ha, Sung Yun Cho, Hyoung Rae Kim, Kwang Ho Lee, Chong Ock Lee, Sang Un Choi, Chi Hoon Park
  • Patent number: 9199944
    Abstract: Disclosed herein are a new N2,N4-bis(4-(piperazin-1-yl)phenyl)pyrimidin-2,4-diamine derivative or a pharmaceutically acceptable salt thereof and a pharmaceutical composition for the prevention or treatment of cancers containing the same as an active ingredient. The compound of the present invention has excellent inhibitory effects against the activities of anaplastic lymphoma kinase (ALK) and activated cdc42-associated kinase (ACK1) and thus can improve the therapeutic effects on the treatment of cancer cells having anaplastic lymphoma kinase fusion proteins such as EML4-ALK and NPM-ALK, and also effectively prevent the recurrence of cancers thus being useful as a pharmaceutical composition for the prevention and treatment of cancers.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: December 1, 2015
    Assignee: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Kwangho Lee, Hyoung Rae Kim, Chi Hoon Park, Chong Ock Lee, Jong Kook Lee, Hee Jung Jung, Sung Yun Cho, Chong Hak Chae, Sang Un Choi, Jae Du Ha
  • Publication number: 20150259350
    Abstract: The present invention relates to a novel triazolopyrazine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating hyper proliferative disorder. The present invention can be useful as a therapeutic agent for various hyper proliferative disorders associated with excessive cell proliferation and growth caused by abnormal kinase activity, such as cancer, psoriasis, rheumatoid arthritis, and diabetic retinopathy, by efficiently inhibiting c-Met tyrosine kinase activity.
    Type: Application
    Filed: September 30, 2013
    Publication date: September 17, 2015
    Inventors: Hee Jung Jung, Jae Du Ha, Sung Yun Cho, Hyoung Rae Kim, Kwang Ho Lee, Chong Ock Lee, Sang Un Choi, Chi Hoon Park
  • Publication number: 20150152069
    Abstract: Disclosed herein are a new N2,N4-bis(4-(piperazin-1-yl)phenyl)pyrimidin-2,4-diamine derivative or a pharmaceutically acceptable salt thereof and a pharmaceutical composition for the prevention or treatment of cancers containing the same as an active ingredient. The compound of the present invention has excellent inhibitory effects against the activities of anaplastic lymphoma kinase (ALK) and activated cdc42-associated kinase (ACK1) and thus can improve the therapeutic effects on the treatment of cancer cells having anaplastic lymphoma kinase fusion proteins such as EML4-ALK and NPM-ALK, and also effectively prevent the recurrence of cancers thus being useful as a pharmaceutical composition for the prevention and treatment of cancers.
    Type: Application
    Filed: February 9, 2015
    Publication date: June 4, 2015
    Inventors: Kwangho LEE, Hyoung Rae KIM, Chi Hoon PARK, Chong Ock LEE, Jong Kook LEE, Hee Jung JUNG, Sung Yun CHO, Chong Hak CHAE, Sang Un CHOI, Jae Du HA
  • Publication number: 20140335439
    Abstract: Disclosed are a polymer ion exchange membrane having a self-hydration capability at a high temperature under low humidity, a method of preparing the polymer ion exchange membrane, and a polymer electrolyte fuel cell system including the polymer ion exchange membrane. The polymer electrolyte membrane includes a hydrocarbon-based proton conductive polymercoating layer, and has a nano-crack on the hydrophobic surface and thus may secure ion conductivity and self-hydration capability under low humidity and remarkably improve electrochemical performance of an electrolyte.
    Type: Application
    Filed: July 23, 2014
    Publication date: November 13, 2014
    Inventors: Young Moo LEE, Chi Hoon Park, Doo Sung Hwang, So Young Lee, Dong Won Shin